The Viet Nam Competition Authority eyed the nation’s pharmaceutical sector at a recent conference, where the regulator addressed the seeming paradox of a low concentration rate but increasing pharmaceutical companies. Reports say the head of the regulator’s Competition Supervision and Management Department spoke about the troublesome pattern of rising prices in the industry, despite the fact that there are nine times more distributors of pharmaceuticals than there are producers – a figure that implies a low concentration rate, usually associated with high competition and lower prices. Tran Phuong Lan stated that merger and acquisition activity could potentially increase competition by allowing foreign rivals into the market.
Featured News
Tokyo Authorities Raid Eneos Wing Office in Expanding Gas Oil Price-Fixing Probe
Mar 10, 2026 by
CPI
States Vow to Continue Antitrust Fight Against Live Nation Despite DOJ Settlement
Mar 9, 2026 by
CPI
White House Cybersecurity Plan Calls on Private Sector to Partner on US Operations
Mar 9, 2026 by
CPI
Big Tech Data Centers Become Wartime Targets After Drone Strikes on Amazon Sites
Mar 9, 2026 by
CPI
Anthropic Sues Pentagon to Block National Security Blacklist Over AI Restrictions
Mar 9, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Behavioral Economics
Feb 22, 2026 by
CPI
Behavioral Antitrust in 2026
Feb 22, 2026 by
Maurice Stucke
Behavioral Economics in Competition Policy: Going Beyond Inertia and Framing Effects
Feb 22, 2026 by
Annemieke Tuinstra & Richard May
Agreeing to Disagree in Antitrust
Feb 22, 2026 by
Jorge Padilla
Recognizing What’s Around the Corner: Merger Control, Capabilities, and the New Nature of Potential Competition
Feb 22, 2026 by
Magdalena Kuyterink & David J. Teece